HIV Drug Candidate Study
Added: Jun 27, 2017 1:38 pm This Small Business Sources Sought Notice is for information and planning purposes only and shall not be construed as a solicitation or as an obligation or commitment by the Government. This notice is intended strictly for Market Research. The National Institutes of Health (NIH) Eunice Kennedy Siver, National Institute of Child Health and Human Development is conducting a market survey to determine the availability and technical capability of qualified small business, veteran-owned small business, service-disabled veteran-owned small business or HUBZone small businesses capable of HIV Drug Candidate Study.The NIDDK has an ongoing project. Proposal will be to study the performance of a new drug that inactivates HIV and perform detailed mechanism-based studies in non-human primates (NHP) infected with SIV. This purchase of antiviral testing is a requirement that must be done by a uniquely qualified company to allow proper evaluation of efficacy and any toxicity in NHP. Lab-to-lab variability is inherent in biological testing, and is uniquely able to handle the drug, responsibly administer it to NHP, and track the effect on SIV.The intended procurement will be classified under North American Industrial Classification (NAICS) code 541711 with a size standard of 1000. All respondents are requested to identify their firm's size and type of business. Interested firms responding to this market survey must provide (a) capability statement demonstrating their experience, skills and capability to fulfill the Government's requirements for the above. The capability statement shall be in sufficient enough detail, but not to exceed 15 pages, so that the Government can determine the experience and capability of your firm to provide the requirements above. Your capability statement, not to exceed 15 pages, should include references. Capability statement must be received at the email address identified in this synopsis by 11:00 A.M. local time on July 5, 2017. Any questions regarding this announcement must be sent via email to verne.griffin@.nih.gov and must include solicitation NICHD2017028 in the subject line of email.This synopsis is for information and planning purposes and is not to be construed as a commitment by the Government, nor will the Government pay for information solicited. Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provided feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate response to a solicitation.Disclaimer and Important Notes: This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provided feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate response to a solicitation. Confidentiality - No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s)." PLEASE NOTE: In order to receive an award, contractor must be registered and have valid certification in the System for Award Management (SAM) http://www.sam.gov NICHD2017028 Department of Health and Human Services National Institutes of Health
6/27/17, 1:38 PM HIV Drug Candidate Study
Added: Aug 04, 2017 6:57 am This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NICHD2017028 and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect tough Federal Acquisition Circular 2005-95. The North American Industry Classification (NAICS) Code is 541380 and the business size standard is $15m. However, this solicitation is not set aside for small business. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. Eunice Kennedy Siver National Institute of Child Health and Human Development (NICHD) intend to procure on a sole source basis with Bioqual, Inc., 4 Research Court, Rockville, MD 20850 to provide HIV Drug Candidate Study:The NIDDK has an ongoing project. Proposal will be to study the performance of a new drug that inactivates HIV and perform detailed mechanism-based studies in non-human primates (NHP) infected with SIV. This purchase of antiviral testing is a requirement that must be done by a uniquely qualified company to allow proper evaluation of efficacy and any toxicity in NHP. Lab-to-lab variability is inherent in biological testing, and is uniquely able to handle the drug, responsibly administer it to NHP, and track the effect on SIV. Proposal will be to study the performance of a new drug that inactivates HIV and perform detailed mechanism-based studies in non-human primates (NHP) infected with SIV. Animals receiving the drug will be monitored for viral load and toxicity.The proposed contract action is for supplies or services for which the Government intends to solicit and negotiate with only one source under authority of the 41 U.S.C. 253(c) (1), FAR 6.302. Only one responsible source and no other supplies or services will satisfy agency requirements.The offeror must include a completed copy of the provision of FAR Clause 52.212-3, Offeror Representations and Certifications - Commercial Items with its offer. The provisions of FAR Clause 52.212-1 Instructions to Offerors - Commercial Items; FAR Clause 52.212-2, Evaluation - Commercial Items; FAR Clause 52.212-4, Contract Terms and Conditions - Commercial Items; and FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders - Commercial Items - Deviation for Simplified Acquisitions applies to this acquisition. The offeror must include their Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The clauses are available in full text at http://www.acquisition.gov/far/. Interested vendors capable of furnishing the government with the services specified in this synopsis should submit a copy of their quotation to the below address or via email to robinsti@mail.nih.gov. Offers must also be accompanied by descriptive literature, delivery/turnaround timeframe, warranties and/or other information that demonstrates that the offer meets all the foregoing requirements. Quotations will be due ten calendar days from the publication date of this synopsis or by August 10, 2017 by 10 am, EST. via email or postal mail. The quotation must reference "Solicitation number" NICHD2017028. Quotations sent by postal mail or other mailing services must be submitted to the following address: Eunice Kennedy Siver National Institute of Child Health and Human Development, 6710B Rockledge Drive, MSC 1159B Bethesda, MD 20892. Attention: Verne Griffin, by the date and time mentioned above. Any questions must be sent via email to verne.griffin@nih.gov and must include solicitation# NICHD2017028 in the subject line of email. Faxed copies/responses will not be accepted.Note: In order to receive an award, contractor must be registered and have valid certification in the SAM database @www.sam.gov. NICHD2017028 Department of Health and Human Services National Institutes of Health
8/4/17, 6:57 AM